Berdazimer Gel (Zelsuvmi) for Molluscum Contagiosum
Berdazimer 10.3% gel (Zelsuvmi – Ligand), a first-in-class nitric oxide-releasing agent, has been approved by the FDA for topical treatment of molluscum contagiosum in patients ≥1 year old. It is the second drug to become available in the US for treatment of molluscum contagiosum and the first that can be applied by the patient or caregiver at home; cantharidin 0.7% solution (Ycanth), which is applied by a healthcare professional, was approved earlier for use in patients ≥2 years old.
Publication Details
- Journal
- The medical letter on drugs and therapeutics/The medical letter
- Published
- 2025-07-21
- DOI
- https://doi.org/10.58347/tml.2025.1733a
- Primary Topic
- Poxvirus research and outbreaks
- Type
- article
- Field-Weighted Citation Impact
- 0.00